Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
1(50.0%)
N/A
1(50.0%)
2Total
Phase 4(1)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06649422Not Yet Recruiting

Reduced-Dose Chemo Followed by 14 Days of Blinatumomab for Newly Diagnosed Adult B-ALL Patients: a Multicenter Study

Role: collaborator

NCT04897126Phase 4Completed

Efficacy and Safety of Shexiang Baoxin Pill in Patients With Ischemia With Non-Obstructive Coronary Artery

Role: collaborator

NCT05835167Not ApplicableNot Yet Recruiting

Complete Revascularization Via Inferior Part-sternotomy

Role: collaborator

NCT04958447Unknown

Nutritional Management in Respiratory Critically Ill Patients -an Observational Study in Mainland China

Role: collaborator

All 4 trials loaded